Compare DexCom, Inc. (DXCM) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? DexCom, Inc. trades at $78.66 (market cap $28.06B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.64. The key difference: DexCom, Inc. is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | VNQI | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $50.76 |
52-Week Low | $54.84 | $43.26 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.56, up 0.49% today, with neutral technical signals from both moving averages and oscillators. The ETF provides international real estate diversification with 682 holdings across 30+ countries, featuring a 0.12% expense ratio and 4.6% dividend yield. Recent analysis highlights its cost advantage over competitors and recovery potential as global real estate transactions are expected to grow over 10% in 2026.
The ETF offers attractive diversification benefits for U.S. investors seeking international real estate exposure at low cost, though it has underperformed domestic counterparts in total returns. Key risks include currency fluctuations, international market volatility, and interest rate sensitivity. Current valuation metrics show P/B of 0.9x and P/E of 11.9x, suggesting reasonable pricing for global real estate assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
